Betsy T. Kren

Minneapolis VA Health Care System — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

39h-index5.2kcitations142works1.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA Interference and Gene Delivery(41), RNA modifications and cancer(22), CRISPR and Genetic Engineering(21), Liver physiology and pathology(21), Cancer-related Molecular Pathways(16)

Publications142 total

Abstract 2995: Inhibition of pyrimidine synthesis and the cell cycle in mesothelioma
Cancer Research·2025
Impact of protein kinase CK2 downregulation and inhibition on oncomir clusters 17 ~ 92 and 106b ~ 25 in prostate, breast, and head and neck cancers
Molecular Medicine·2024· 3 citedOpen Access
Cyclin D1 extensively reprograms metabolism to support biosynthetic pathways in hepatocytes
Journal of Biological Chemistry·2023· 6 citedOpen Access
Delivery of RNP complexes for CRISPRi (dCas9) silencing in vitro and in vivo using crystalline ultrasmall particles (CUSP)
2023Open Access
Inhibition of Mitochondrial Antioxidant Defense and CDK4/6 in Mesothelioma
Molecules·2023· 5 citedOpen Access
Supplementary Table 2 from Mechanism and Efficacy of Sub–50-nm Tenfibgen Nanocapsules for Cancer Cell–Directed Delivery of Anti-CK2 RNAi to Primary and Metastatic Squamous Cell Carcinoma
2023Open Access
Supplementary Figure 2 from Mechanism and Efficacy of Sub–50-nm Tenfibgen Nanocapsules for Cancer Cell–Directed Delivery of Anti-CK2 RNAi to Primary and Metastatic Squamous Cell Carcinoma
2023Open Access
Supplementary Figure Legends from Mechanism and Efficacy of Sub–50-nm Tenfibgen Nanocapsules for Cancer Cell–Directed Delivery of Anti-CK2 RNAi to Primary and Metastatic Squamous Cell Carcinoma
2023Open Access
Data from Mechanism and Efficacy of Sub–50-nm Tenfibgen Nanocapsules for Cancer Cell–Directed Delivery of Anti-CK2 RNAi to Primary and Metastatic Squamous Cell Carcinoma
2023Open Access
Supplementary Figure 1 from Mechanism and Efficacy of Sub–50-nm Tenfibgen Nanocapsules for Cancer Cell–Directed Delivery of Anti-CK2 RNAi to Primary and Metastatic Squamous Cell Carcinoma
2023Open Access
Supplementary Figure 1 from Mechanism and Efficacy of Sub–50-nm Tenfibgen Nanocapsules for Cancer Cell–Directed Delivery of Anti-CK2 RNAi to Primary and Metastatic Squamous Cell Carcinoma
2023Open Access
Supplementary Figure 2 from Mechanism and Efficacy of Sub–50-nm Tenfibgen Nanocapsules for Cancer Cell–Directed Delivery of Anti-CK2 RNAi to Primary and Metastatic Squamous Cell Carcinoma
2023Open Access
Supplementary Table 3 from Mechanism and Efficacy of Sub–50-nm Tenfibgen Nanocapsules for Cancer Cell–Directed Delivery of Anti-CK2 RNAi to Primary and Metastatic Squamous Cell Carcinoma
2023Open Access
Data from Mechanism and Efficacy of Sub–50-nm Tenfibgen Nanocapsules for Cancer Cell–Directed Delivery of Anti-CK2 RNAi to Primary and Metastatic Squamous Cell Carcinoma
2023Open Access
Supplementary Table 2 from Mechanism and Efficacy of Sub–50-nm Tenfibgen Nanocapsules for Cancer Cell–Directed Delivery of Anti-CK2 RNAi to Primary and Metastatic Squamous Cell Carcinoma
2023Open Access
Supplementary Table 1 from Mechanism and Efficacy of Sub–50-nm Tenfibgen Nanocapsules for Cancer Cell–Directed Delivery of Anti-CK2 RNAi to Primary and Metastatic Squamous Cell Carcinoma
2023Open Access
Supplementary Table 3 from Mechanism and Efficacy of Sub–50-nm Tenfibgen Nanocapsules for Cancer Cell–Directed Delivery of Anti-CK2 RNAi to Primary and Metastatic Squamous Cell Carcinoma
2023Open Access
Supplementary Table 1 from Mechanism and Efficacy of Sub–50-nm Tenfibgen Nanocapsules for Cancer Cell–Directed Delivery of Anti-CK2 RNAi to Primary and Metastatic Squamous Cell Carcinoma
2023Open Access
Supplementary Figure Legends from Mechanism and Efficacy of Sub–50-nm Tenfibgen Nanocapsules for Cancer Cell–Directed Delivery of Anti-CK2 RNAi to Primary and Metastatic Squamous Cell Carcinoma
2023Open Access
Correction: Protein kinase CK2 – diverse roles in cancer cell biology and therapeutic promise
Molecular and Cellular Biochemistry·2022· 1 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Clifford J. Steer(37), Cecília M. P. Rodrigues(14), Janeen H. Trembley(11), Rui E. Castro(8), Khalil Ahmed(7), Phillip Wong(6), Xiaoming Ma(6), Gretchen M. Unger(6), Susana Solá(5), Walter C. Low(4), Vicci L. Korman(4), Cheryle Linehan-Stieers(3), Pedro M. Borralho(3), Paramita Bandyopadhyay(3), Jeffrey H. Albrecht(3), Guo‐Chang Fan(2), Guangsheng Fan(2), Aaron L. Sarver(2), Xiaoxiao Zhang(2), Yan Zeng(2)